Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunogenicity Study of the Antibody Persistence and Booster Effect of PENTAXIM(TM) at 18 Months of Age Following a Primary Series of DTaP-IPV-HB-PRP~T Combined Vaccine or of PENTAXIM(TM) and ENGERIX B(R) PEDIATRICO at 2, 4, and 6 Months of Age in Healthy Argentinean Infants. [EXTENSION of 700041122]

Trial Profile

Immunogenicity Study of the Antibody Persistence and Booster Effect of PENTAXIM(TM) at 18 Months of Age Following a Primary Series of DTaP-IPV-HB-PRP~T Combined Vaccine or of PENTAXIM(TM) and ENGERIX B(R) PEDIATRICO at 2, 4, and 6 Months of Age in Healthy Argentinean Infants. [EXTENSION of 700041122]

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Mar 2013

At a glance

  • Drugs Hib-DTaP-poliovirus vaccine (Primary)
  • Indications Diphtheria; Hepatitis B; Pertussis; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors Sanofi
  • Most Recent Events

    • 15 Dec 2009 Actual end date (Sep 2007) and actual number of patients (459) added as reported by ClinicalTrials.gov.
    • 15 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Nov 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top